He will receive the medal during Innovation Day 2010 at the Chemical Heritage Foundation (CHF) in Philadelphia on 23 September in front of more than 200 scientific leaders from the chemical and molecular science industries.
‘Ron Breslow combines brilliance in research with great effectiveness in telling the story of the achievements of chemistry to all who will listen,’ said Sunil Kumar, president and ceo of International Specialty Products.
‘He is the central architect of two major areas of research: biomimetic systems and nonbenzenoid aromatic chemistry. His work offers promise of important breakthroughs in the fight against cancer by modulating gene transcription in cancer cells.’
For more than 50 years, Breslow has been a member of the faculty of Columbia University, which he joined after studying at Harvard. He has been active on many levels in the National Academy of Sciences (Chairman of the Chemistry Division 1974–77) and the American Chemical Society (ACS president, 1996; Priestley Medal, 1999).
The SCI Perkin Medal is recognised as the highest honour given for outstanding work in applied chemistry in the US. It commemorates the discovery of the first synthetic dye (the so-called Perkin mauve) by Sir William Henry Perkin in 1856. This discovery was a significant step forward in organic chemistry that led to the birth of a major segment of the chemical industry.
The Perkin Medal was first awarded to Sir William at a banquet held by the SCI in New York in 1906. Since then, more than 100 such awards have been given to notable scientists.
SCI awards Perkin Medal to Ronald Breslow
In recognition of his research into biomimetic systems and nonbenzenoid aromatic chemistry
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Research & Development
Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption
A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing
Degasser for volatile and aggressive solvents
Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development
Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer
The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies